Huapont Life Science Co (SZSE:002004) Cash-to-Debt : 0.51 (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Huapont Life Science Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Huapont Life Science Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.51.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Huapont Life Science Co couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Huapont Life Science Co's Cash-to-Debt or its related term are showing as below:

SZSE:002004' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.45 Med: 0.58 Max: 0.94
Current: 0.51

During the past 13 years, Huapont Life Science Co's highest Cash to Debt Ratio was 0.94. The lowest was 0.45. And the median was 0.58.

SZSE:002004's Cash-to-Debt is ranked worse than
54.39% of 239 companies
in the Agriculture industry
Industry Median: 0.63 vs SZSE:002004: 0.51

Huapont Life Science Co Cash-to-Debt Historical Data

The historical data trend for Huapont Life Science Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Huapont Life Science Co Cash-to-Debt Chart

Huapont Life Science Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.45

0.54

0.63

0.61

0.51

Huapont Life Science Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.59	0.56	0.53	0.51	0.51

Competitive Comparison of Huapont Life Science Co's Cash-to-Debt

For the Agricultural Inputs subindustry, Huapont Life Science Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Huapont Life Science Co's Cash-to-Debt Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Huapont Life Science Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Huapont Life Science Co's Cash-to-Debt falls into.

Huapont Life Science Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Huapont Life Science Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4413.135	/	(5693.755	+	2932.089)
	=	0.51

Huapont Life Science Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4901.933	/	(6794.155	+	2855.455)
	=	0.51

Huapont Life Science Co (SZSE:002004) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Huapont Life Science Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Huapont Life Science Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Huapont Life Science Co (SZSE:002004) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Huapont Life Science Co Ltd (SZSE:002004) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 69, Renhe Xingguang Avenue, Yubei District, Chongqing, CHN, 401121

Website

http://www.huapont.com.cn

Huapont Life Science Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. In addition, the company is also engaged in the agrochemical business and medical business. The agrochemical department is mainly engaged in the research and development, production, sales, and technical services of pesticide intermediates, original drugs, and preparations.

Executives

Zhang Hai An	Directors, executives
Wang Rong	Director
Yu Jun Tian	Director
Zhang Song Shan	Directors, executives
Chen Zhi	Securities Affairs Representative
Jiang Kang Wei	Director
Lv Li Ming	Director
Li Sheng Xue	Director
Luo Da Lin	Supervisors
Li Zhi	Directors, executives
Tian Song Min	Executives
Wu Bi Zhong	Director
Yu Yun Jian	Supervisors
Gu Chuan Wei	Supervisors

Huapont Life Science Co (SZSE:002004) Headlines

No Headlines